The predictive value of normal EEGs in dementia due to Alzheimer’s disease

Abstract

Objective To determine differences in clinical presentation and disease progression between patients with dementia due to AD with visually normal and abnormal EEG recordings. We hypothesized that patients with normal electroencephalographs (EEGs) are a representation of the heterogeneity of AD. We expected this group to have a phenotype with relatively predominant hippocampal atrophy, memory deficits, and a slower disease progression. Methods Patients were included based on diagnosis of dementia due to AD, positive amyloid and tau cerebrospinal fluid (CSF) biomarkers, and the availability of EEG recordings. Patients were categorized in groups of normal (N = 208) and abnormal (N = 336) EEG recordings based on visual assessment by experienced neurophysiologists. At baseline demographics, cognitive, MRI, and CSF measures were compared between groups. Cognitive data from follow‐up visits were assessed by linear mixed‐effects models (LMMs), and corrected for baseline value, sex, age, and educational level, to compare cognitive deterioration over time between groups. Results About 1 in 4.5 patients with AD dementia had a visually normal EEG and this group showed better overall cognitive performance compared to the abnormal group, where memory was the most prominent affected domain. The normal group showed less global and parietal but similar medial temporal atrophy. Follow‐up data showed a slower deterioration on all tested cognitive domains in the normal EEG group. Interpretation Patients with dementia due to AD and visually normal EEG recordings showed a milder clinical presentation and had a milder disease progression compared to patients with an abnormal EEG. These results provide evidence of clinical and biological heterogeneity within AD dementia.

Biomarkers for Alzheimer’s Disease: Context of Use, Qualification, and Roadmap for Clinical Implementation

“…Mechanistically nonspecific evidence of target engagement can be garnered from electroencephalography (EEG), evoked potentials, and functional MRI (fMRI) [ 66 , 67 , 68 , 69 ]. The restoration or slowing of deterioration of these measures suggest that circuit function has been beneficially affected compared to placebo, demonstrate that the drug has entered the brain, provide preliminary evidence in support of the POC of drug activity, and may show drug–placebo differences in smaller samples than those required to demonstrate clinical effects.…”

Longitudinal resting-state EEG in amyloid-positive patients along the Alzheimer’s disease continuum: considerations for clinical trials

“…The degree of EEG abnormalities has been shown to correlate strongly with cognitive impairment in AD patients, in both cross-sectional [ 26 ] and longitudinal studies [ 27 ]. Several measures, including relative power [ 11 , 28 ], the spectral power ratio ( delta/theta + alpha/beta power) [ 29 ], spectral coherence [ 30 ], and complexity [ 31 ], have shown significant associations with neuropsychological measures.…”